Jefferies analyst Brent Thill initiates coverage on Progress Software (NASDAQ:PRGS) with a Hold rating and announces Price Target of $52.
Cocrystal Pharma Receives UK MHRA Authorization To Initiate Its Phase 2a Influenza Human Challenge Trial With Oral PB2 Inhibitor CC-42344
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge
